These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25164908)

  • 41. Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
    Ceribelli A; Pino MS; Gelibter AJ; Milella M; Cecere FL; Caterino M; Facciolo F; Mirri A; Cognetti F
    Cancer; 2007 Feb; 109(4):727-31. PubMed ID: 17238182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
    Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
    Georgoulias V; Samonis G; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Grigoratou T; Palamidas P; Kouroussis C; Mavroudis D; Kakolyris S; Giannakakis T; Vlachonikolis J;
    Lung Cancer; 2001 Dec; 34 Suppl 4():S47-51. PubMed ID: 11742702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
    Corre R; Greillier L; Le Caër H; Audigier-Valette C; Baize N; Bérard H; Falchero L; Monnet I; Dansin E; Vergnenègre A; Marcq M; Decroisette C; Auliac JB; Bota S; Lamy R; Massuti B; Dujon C; Pérol M; Daurès JP; Descourt R; Léna H; Plassot C; Chouaïd C
    J Clin Oncol; 2016 May; 34(13):1476-83. PubMed ID: 26884557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
    Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
    Morère JF; Bréchot JM; Westeel V; Gounant V; Lebeau B; Vaylet F; Barlési F; Urban T; Souquet PJ; Debieuvre D; Baudrin L; Zalcman G; Morin F; Milleron B; Moro-Sibilot D
    Lung Cancer; 2010 Dec; 70(3):301-7. PubMed ID: 20400201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
    Li Y; Wang LR; Chen J; Lou Y; Zhang GB
    Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
    Zwitter M; Kovac V; Rajer M; Vrankar M; Smrdel U
    Anticancer Drugs; 2010 Jul; 21(6):662-8. PubMed ID: 20453635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
    Wang XQ; Liu J; Lin HS; Hou W
    Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
    Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
    Paz-Ares L; Socinski MA; Shahidi J; Hozak RR; Soldatenkova V; Kurek R; Varella-Garcia M; Thatcher N; Hirsch FR
    Ann Oncol; 2016 Aug; 27(8):1573-9. PubMed ID: 27207107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
    Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
    Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
    Gridelli C; Ciardiello F; Gallo C; Feld R; Butts C; Gebbia V; Maione P; Morgillo F; Genestreti G; Favaretto A; Leighl N; Wierzbicki R; Cinieri S; Alam Y; Siena S; Tortora G; Felletti R; Riccardi F; Mancuso G; Rossi A; Cantile F; Tsao MS; Saieg M; da Cunha Santos G; Piccirillo MC; Di Maio M; Morabito A; Perrone F
    J Clin Oncol; 2012 Aug; 30(24):3002-11. PubMed ID: 22778317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
    Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V
    Ann Oncol; 2004 Jan; 15(1):19-27. PubMed ID: 14679114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
    Wei Z; Yang X; Ye X; Feng Q; Xu Y; Zhang L; Sun W; Dong Y; Meng Q; Li T; Wang C; Li G; Zhang K; Li P; Bi J; Xue G; Sun Y; Sheng L; Liu B; Yu G; Ren H; Wang J; Sun L; Chen S; Geng D; Zhang B; Xu X; Zhang L; Sun D; Xu X; Diao C; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zheng A; Fan W; Li Y; Li F; Fan H; Zou Z; Li Q; Tian H
    Eur Radiol; 2020 May; 30(5):2692-2702. PubMed ID: 32020400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.